AZ CHINOOK
Summary
This trial will study a drug called benralizumab. The researchers want to know if benralizumab is useful in treating severe asthma. To see if benralizumab has an impact in treating severe asthma, this study will compare it with placebo. The placebo will be like benralizumab but will not contain any active medication.
Benralizumab is an approved treatment for asthma in Canada, US, Europe, and other countries under the trade name Fasenra.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 65
Inclusion criteria:
You might be eligible to participate in this trial if:
1) you are 18-65 years of age
2) you have asthma
Exclusion criteria:
You might not be eligible to participate in this trial if:
1) you do not have asthma
2) you are pregnant
3) you are not between 18-65 years of age.
Participate
Additional information
Contact information
If you would like to learn more about how you can get involved with this trial, please contact our study coordinator Curtis at 403-220-2123.
Principal investigator:
James Ramsahai
Clinical trial:
Yes
REB-ID:
REB19-1331